UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 15

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g)

OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER

SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number: 0-24241

PANACOS PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

134 Coolidge Avenue

Watertown, Massachusetts 02472

(Address of Principal Executive Offices)

(617) 926-1551

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

Common Stock, $0.01 Par Value

(Title of each class of securities covered by this Form)

None

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

 

Rule 12g-4(a)(1)    x   
Rule 12g-4(a)(2)    ¨   
Rule 12h-3(b)(1)(i)    x   
Rule 12h-3(b)(1)(ii)    ¨   
Rule 15d-6    ¨   

Approximate number of holders of record as of the certification or notice date: 140

Pursuant to the requirements of the Securities Exchange Act of 1934, Panacos Pharmaceuticals, Inc. has caused this certification and notice to be signed on its behalf by the undersigned duly authorized person.

 

 

Date: March 19, 2009   By:   /s/ Alan W. Dunton, M.D.         
   

Alan W. Dunton, M.D.

President and Chief Executive Officer

Grafico Azioni Panacos Pharmaceuticals (CE) (USOTC:PANC)
Storico
Da Mag 2024 a Giu 2024 Clicca qui per i Grafici di Panacos Pharmaceuticals (CE)
Grafico Azioni Panacos Pharmaceuticals (CE) (USOTC:PANC)
Storico
Da Giu 2023 a Giu 2024 Clicca qui per i Grafici di Panacos Pharmaceuticals (CE)